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P. aeruginosa forms biofilms in the lungs of individuals with cystic fibrosis (CF); however, there have been no
effective model systems for studying biofilm formation in the CF lung. We have developed a tissue culture system
for growth of P. aeruginosa biofilms on CF-derived human airway cells that promotes the formation of highly
antibiotic-resistant microcolonies, which produce an extracellular polysaccharide matrix and require the known
abiotic biofilm formation genes flgK and pilB. Treatment of P. aeruginosa biofilms with tobramycin reduced the
virulence of the biofilms both by reducing bacterial numbers and by altering virulence gene expression. We
performed microarray analysis of these biofilms on epithelial cells after treatment with tobramycin, and we
compared these results with gene expression of (i) tobramycin-treated planktonic P. aeruginosa and (ii) tobramycintreated P. aeruginosa biofilms on an abiotic surface. Despite the conservation in functions required to form a biofilm,
our results show that the responses to tobramycin treatment of biofilms grown on biotic versus abiotic surfaces are
different, as exemplified by downregulation of genes involved in Pseudomonas quinolone signal biosynthesis specifically in epithelial cell-grown biofilms versus plastic-grown biofilms. We also identified the gene PA0913, which is
upregulated by tobramycin specifically in biofilms grown on CF airway cells and codes for a probable magnesium
transporter, MgtE. Mutation of the PA0913 gene increased the bacterial virulence of biofilms on the epithelial cells,
consistent with a role for the gene in the suppression of bacterial virulence. Taken together, our data show that analysis
of biofilms on airway cells provides new insights into the interaction of these microbial communities with the host.
tion into the genetic regulatory networks governing this transition between acute and chronic infection might assist in our
understanding of P. aeruginosa persistence in the CF lung.
P. aeruginosa biofilm formation has been extensively studied
on abiotic surfaces using a variety of static and flow cell assays
(35). These investigations have revealed a multistep process
leading to formation of bacterial communities attached to the
abiotic substratum. However, a more relevant model system in
which to study P. aeruginosa biofilm formation and virulence in
the context of CF airway cells would be useful in order to
understand airway infection in CF.
To better understand P. aeruginosa infection in the context of
the CF airway epithelium, we developed a tissue culture-based
system in which to study P. aeruginosa biofilm formation on human CF-derived lung epithelial cells in vitro. We report that
tobramycin decreases the virulence of P. aeruginosa growing on
human CF airway epithelial cells. Microarray analysis showed that
the genes required for biogenesis of Pseudomonas quinolone signal (PQS), an important signaling molecule regulating virulence
gene expression, are downregulated upon tobramycin treatment,
specifically within the context of a biofilm grown on airway cells.
We also identified a putative magnesium transporter that is involved in bacterial virulence toward the epithelial cells. Furthermore, our results show that the responses of P. aeruginosa to
tobramycin treatment are markedly different depending upon
whether the microbe is growing planktonically, in a biofilm on an
abiotic surface, or in a biofilm on epithelial cells.

Pseudomonas aeruginosa is adept at establishing chronic infections in the lungs of individuals with cystic fibrosis (CF). CF
is a common inherited genetic disorder, and pathology in the
disease is brought about by improper chloride secretion due to
mutations in the CF transmembrane conductance regulator
(CFTR) (4, 14, 23). In the lung, this chloride transport defect,
and the resulting altered airway physiology, lead to impairment
of mucociliary clearance and production of thick mucus plugs
in the airways (14, 16, 38, 51). These reactions predispose the
CF patient to chronic microbial infection, and P. aeruginosa
eventually becomes the dominant infecting microorganism
from childhood through adulthood (14, 30). Despite the availability and aggressive use of antibiotics, P. aeruginosa colonization often becomes lifelong and is a major factor contributing to CF patient complications, including respiratory failure
and death (14, 30, 38).
Current evidence suggests that one significant reason for the
persistence of P. aeruginosa is its ability to form antibioticresistant biofilms in the lungs of CF patients. Indeed, antibiotic
resistance profiles, quorum-sensing studies, and microscopic
examination of microcolonies in CF patient lungs support this
hypothesis (16, 22, 25, 38, 43). Biofilm formation is the result
of global regulatory changes within the bacterium as a result of
the harsh lung environment, and the appearance of P. aeruginosa biofilms correlates with chronic infection (18). Investiga-
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MATERIALS AND METHODS
Bacterial strains and plasmids. The strains and plasmids used in this study are
listed in Table S1 in the supplemental material. For all experiments, except for
pyoverdine assays, bacteria were grown in LB overnight with appropriate anti-
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biotics. Pyoverdine assays were performed using cultures grown overnight in
King’s B medium (20 g/liter proteose peptone, 10 g/liter glycerol, 1.5 g/liter
KH2PO4, 1.5 g/liter MgSO4), and overnight cultures were adjusted to similar
optical densities at 600 nm (OD600) prior to assays. Wild-type P. aeruginosa PA14
and ⌬PA0913 strains exhibited similar growth kinetics (data not shown).
Static coculture biofilm assay. CFBE41o⫺ cells (CFBE cells) are human
bronchial epithelial cells that are homozygous for the ⌬F508 mutation of CFTR
(5, 8). P. aeruginosa biofilms were grown on CFBE cells using a coculture model
system. In this model, epithelial cells were seeded at a concentration of 106
cells/well in 6-well tissue culture plates or 2 ⫻ 105 cells/well in 24-well tissue
culture plates and maintained in minimal essential medium (MEM) (Mediatech,
Herndon, VA) with 10% fetal bovine serum, 2 mM L-glutamine, 50 U/ml penicillin, and 50 g/ml streptomycin. The cells were grown at 37°C and 5% CO2 for
7 to 10 days before inoculation with bacteria. These conditions have been shown
to lead to confluent cell monolayers and to allow the formation of tight junctions
(5, 8). P. aeruginosa was inoculated at a concentration of approximately 2 ⫻ 107
CFU/ml into 1.5 ml MEM/well (without fetal bovine serum, penicillin, or streptomycin) for 6-well plates or 1.2 ⫻ 107 CFU/ml in 0.5 ml MEM/well for 24-well
plates. These concentrations were equal to a multiplicity of infection of approximately 30:1 for both plate sizes relative to the number of epithelial cells originally seeded. The plates were incubated for 1 h at 37°C and 5% CO2. After 1 h,
the supernatant was replaced with fresh MEM supplemented with 0.4% arginine,
and the system was incubated at 37°C and 5% CO2 for the times indicated for
each experiment. Epithelial-monolayer integrity was assessed by phase-contrast
microscopy using a Leica DM IRB inverted microscope (Leica Microsystems,
Wetzlar, Germany), and PA14 biofilm formation on CFBE cells was visualized by
fluorescence microscopy examination of cocultures inoculated with P. aeruginosa
PA14 carrying plasmid pSMC21, which constitutively expresses green fluorescent
protein (GFP) (2). Images were analyzed with OpenLab 4.0.4 software (Improvision, Lexington, MA). To determine the numbers of biofilm CFU, we washed
the cells two or three times with phosphate-buffered saline (PBS) to remove
planktonic bacteria and treated the cells with 0.1% Triton X-100 for 10 to 15 min
to lyse the epithelial cells. The lysate was vortexed for 3 min, serially diluted, and
plated on LB. Calcofluor staining was accomplished by diluting a 1% solution of
calcofluor (Fluorescent Brightener 28; Sigma, St. Louis, MO) 1:1,000 in the static
coculture supernatant (52). Staining was assessed by microscopic examination
after incubation with calcofluor for 1 h at 37°C.
Microarray analysis. For microarray analysis of CFBE/P. aeruginosa biofilms,
coculture static biofilms were grown for 9 h in six-well tissue culture plates,
whereupon the cells were washed two or three times with 2 ml PBS, and then
fresh MEM was added. Replicate samples were then incubated in the presence
or absence of 500 g/ml tobramycin, a concentration approximately one-half that
observed in the lungs of CF patients treated with tobramycin (13), for 30 min.
The cells were then washed two or three times with 2 ml PBS, and RNA was
harvested using a modification of the protocol from the RNeasy RNA isolation
kit (Qiagen, Valencia, CA). Specifically, the cells were incubated with 600 l of
1 g/ml lysozyme in Tris-EDTA buffer for 10 min at room temperature. Then,
the cells were homogenized with 600 l RLT lysis buffer from the Qiagen
RNeasy kit, and the homogenate was vortexed for several seconds and drawn
through a 20-gauge needle 10 times. Six hundred microliters of 100% ethanol
was then added, and the solution was applied to an RNeasy column. From this
point, we followed the manufacturer’s protocol for isolation of bacterial RNA.
Mammalian RNA was removed using the MicrobEnrich kit (Ambion, Austin,
TX) according to the manufacturer’s protocol. cDNA synthesis and microarray
preparation, scanning, and analysis were carried out as previously described (24).
Importantly, the multiwell format of the static model system allowed us to
combine the RNAs harvested from several identical wells into one sample in
order to increase the yield. In this manner, we were able to obtain sufficient
high-quality RNA from the bacterial biofilm to carry out microarray analysis.
For microarray analysis of planktonic bacteria, we used mid-exponential phase
cultures of P. aeruginosa PA14. This was achieved by growing P. aeruginosa in 10
ml MEM/2% LB until mid- to late exponential phase, diluting this bacterial
culture 1:4 in fresh MEM/2% LB, and growing it for an additional 3 to 4 h to
reach mid-exponential phase. Replicate cultures were incubated in the presence
or absence of 5 g/ml tobramycin for 30 min at 37°C. Bacterial RNA was then
isolated and prepared for microarray analysis as previously described (24).
Raw microarray data were processed using a Bayesian analysis, as previously
described (24). We chose a ⫾2.0-fold cutoff, as well as a natural log (ln) P value
of ⬍0.05, to identify significantly upregulated and downregulated genes. Data
sets were compared using VennMaster (http://www.informatik.uni-ulm.de/ni
/staff/HKestler/vennm/doc.html).
RT-PCR analysis. For transcriptional analysis of abiotic biofilms, we grew
PA14 in six-well tissue culture plates using MEM supplemented with 0.4%

INFECT. IMMUN.
arginine, as described above for biofilms on CFBE cells, except without epithelial
cells. The abiotic biofilms were grown for 24 h at 37°C and 5% CO2 to reach
approximately 107 to 108 CFU/well, similar to conditions for CFBE biofilm and
planktonic microarray experiments as described above. These abiotic biofilms
were washed twice with PBS and treated with 1 g/ml tobramycin for 30 min at
37°C and 5% CO2. RNA was harvested, and cDNA was synthesized as described
above. Notably, we found that the MicrobEnrich procedure was not needed to
obtain bacterial RNA of sufficient concentration and quality for reverse transcriptase (RT) PCR (data not shown). Quantitative RT-PCR (qRT-PCR) was
carried out as previously described (24) using primer pairs 913forRT/913revRT,
3330for/3330rev, 4326forRT/4326revRT, 4635for/4635rev, 4761forRT/4671revRT,
PA5110for/PA5110rev, 5470for/5470rev, fptA1/fptA2, pqsAF1/pqsAR1, PA0044f/
PA0044r, PA1706f/PA1706r, and PA1707F/PA1707R (see Table S2 in the supplemental material). Primers for fbp (PA5110, encoding fructose bisphosphatase)
were used as a normalization control, because analysis of several data sets in our
laboratory indicated that the transcript levels of the gene remained constant,
regardless of the growth conditions tested (data not shown).
Transcriptional analysis of PA0913 was accomplished by semiquantitative RTPCR. RNA was harvested from 6- to 9-h CFBE/PA14 biofilms or mid-exponential-phase planktonic PA14 cultures treated with tobramycin for 30 min, as
described above for microarray analysis. cDNA synthesis and semiquantitative
RT-PCR were performed as previously described (24, 32), using primer pair
913forRT/913revRT (see Table S2 in the supplemental material) at an annealing
temperature of 56°C. We assayed fbp as a constitutive control.
Genetic constructs. (i) Gene deletions. Isogenic deletion mutants were created
by allelic replacement, using suicide vectors that were assembled by single-step
recombination of PCR fragments in Saccharomyces cerevisiae (41). Briefly, approximately 1,000 bp of 5⬘ and 3⬘ flanking regions for the target genes were PCR
amplified using primer pairs 913Lfor/913Lrev, 913Rfor/913Rrev, 4635Rfor/
4635Rrev, 5470Lfor/5470Lrev, 5470Rfor/5470Rrev, 3819Lfor/3819Lrev, 3819Rfor/
3819Rrev, 4690igLfor/4690igLrev, 4690igRfor/4690igRrev, 4825Lfor/4825Lrev,
4825Rfor/4825Rrev, 3531Lfor/3531Lrev, 3531Rfor/3531Rrev, 4826Lfor/4826Lrev,
and 4826Rfor/4826Rrev (see Table S2 in the supplemental material). Allelic-replacement vector pMQ30 (41) was digested with BamHI and EcoRI, and the digested vector, as well as 5⬘ and 3⬘ PCR fragments, was transformed into S. cerevisiae
strain InvSc1 (Invitrogen, Carlsbad, CA) using an improved “lazybones” protocol, as
previously described (41). This technique resulted in in vivo homologous recombination of vector and PCR fragments, thus creating deletion plasmids for the target
genes (see Table S1 in the supplemental material). The isolated plasmids were
transformed by electroporation into Escherichia coli strain S17-1. S17-1 transformants were conjugated with P. aeruginosa PA14 using standard techniques (24), and
PA14 exconjugants were selected on LB plates containing gentamicin and nalidixic
acid. At this point, the deletion constructs were integrated onto the bacterial chromosome at the gene locus via a single-crossover recombination event. These strains
were grown overnight in liquid culture, and excision of the insert was accomplished
by plating them on LB plates containing 10% sucrose to select for strains that had
lost the sacB gene located on the suicide vector. This indicated that an allele
replacement had occurred. The gene deletion was confirmed by PCR using primer
pairs 913for/913rev, 4635For/4635Rev, 5470For/5470Rev, 3819for/3819rev, 4690for/
4690rev, 4825for/4825rev, 3531for/3531rev, and 4826for/4826rev (see Table S2 in the
supplemental material).
(ii) Complementation vectors. To complement the isogenic PA0913 deletion
strain, the full-length PA0913 gene was PCR amplified using primer pair
913Cfor/913Crev (see Table S2 in the supplemental material). This fragment
included approximately 500 bp upstream of the start codon, so that the natural
promoters might be incorporated into the complementing construct. We digested this PCR fragment with EcoRI and ligated it into the EcoRI-restricted
expression vector pMQ72 (41). The orientation of the fragment was determined
by PCR and sequencing with primers F-t1t2 and R-Pbad (41). The insert oriented in the same direction as the PBAD promoter was considered an inducible
complementing clone (pSMC235), and insertion in the opposite orientation was
used as a natural promoter expression clone (pSMC237). Cloning was carried out
in E. coli strain DH5␣. The PA0913 (mgtE) isogenic deletion mutant was transformed with these constructs by electroporation.
Cytotoxicity assays. The cytotoxicity of PA14 and the isogenic mutants was
assessed by measuring lactate dehydrogenase (LDH) released from epithelial
cells in coculture with the bacteria. Static biofilms were developed on CFBE cells
for the times indicated in the text, and 400 l of the culture medium was
harvested. This medium was centrifuged to pellet bacteria and cell debris, and
300 l of the supernatant was saved. LDH levels within this cell-free supernatant
were assayed using the CytoTox 96 nonradioactive cytotoxicity assay (Promega,
Madison, WI) according to the manufacturer’s instructions. Assays were per-
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formed in triplicate or quadruplicate, and the data represent at least three
identical assays.
Exofactor assays. Pyoverdine was assayed from density-matched overnight
cultures grown in King’s B medium. Culture supernatants were passed through
0.22-m filters, and the relative pyoverdine concentration was determined by
measuring the OD404 (12). Pyocyanin production was assayed similarly to published methods (9). Briefly, density-matched overnight cultures grown in LB were
filtered through 0.22-m filters. Pyocyanin was chloroform extracted using equal
volumes of culture filtrate and chloroform. After being vortexed for 30 seconds,
the solutions were centrifuged for 2 min, and 200 l of the bottom, organic layer
was collected. The solutions were vortexed a second time for 30 seconds and
centrifuged for 2 min; 300 l of the organic phase was recovered and added to
the previously collected 200 l, 500 l of 0.1 N HCl was added to this organic
phase, and pyocyanin was extracted into the aqueous phase by 30 seconds of
vortexing. Four hundred microliters of the upper, aqueous phase was combined
with 600 l 200 mM Tris-HCl, pH 8.0, and the relative pyocyanin concentration
was determined by measuring the OD376. Protease and lipase activities were
assessed by measuring the zone of clearance after overnight incubation of 5 l of
density-matched overnight cultures in 3% skim milk/LB agar plates or 0.5%
tributyrin emulsion agarose plates, respectively (12, 20). Tributyrin agarose
plates were made by sonicating 1% tributyrin in 20 mM HEPES-500 mM NaCl,
pH 7.4, for 3 min. The resultant emulsion was mixed with an equal volume of 20
mM HEPES-500 mM NaCl, pH 7.4, and 2% melted agarose, and the solution
was poured into petri plates to solidify. Each of these assays was performed a
minimum of three times using triplicate cultures.
Biofilm formation. Bacterial viable counts in biofilms in coculture with CFBE
cells were determined as described above (see “Static coculture biofilm assay”).
Formation and assessment of bacterial biofilms on polyvinyl chloride (PVC)
plastic microtiter plates were performed using the crystal violet assay as previously described (34).
Microarray data accession number. Full microarray data for both the CFBE
biofilm and planktonic experiments were deposited in the NCBI (GEO accession
no. GSE10030).

RESULTS
Biofilm formation on CFBE cells. To investigate the interactions between P. aeruginosa and CF airway cells, we developed an in vitro model system of biofilm formation on epithelial cells. We grew CFBE cells, a human bronchial epithelial
cell line with a CFTR ⌬F508/⌬F508 genotype (5, 8), in standard multiwell (6-well and 24-well) tissue culture plates, in
which they formed monolayers. These monolayers were inoculated with P. aeruginosa strain PA14 (referred to throughout
as “PA14”), and biofilm formation was monitored in this static
system over time by phase-contrast microscopy.
In initial studies, uninfected epithelial cells formed confluent
monolayers (Fig. 1A), but after 4 to 6 h of exposure to PA14,
most epithelial cells had lifted off the plastic, leaving only small
patches of cells separated by large sections of empty space
(Fig. 1B). This cell death presumably arose from bacterial
killing of the airway cells and precluded the formation of biofilms. The type III secretion system (T3SS) of P. aeruginosa
greatly affects bacterial virulence, and it is known to exert
cytotoxic effects on epithelial cells (37, 39, 49). Based on data
presented below, it seems likely that the T3SS might have been
involved in the cell death we observed in our assays.
In an effort to identify conditions that delay bacterial killing
of epithelial cells and thus support biofilm formation, we
looked to models of biofilm formation on abiotic surfaces. The
addition of arginine to minimal growth medium enhances the
formation of P. aeruginosa biofilms on PVC plastic surfaces (6).
We predicted by analogy that arginine might exert a similar
biofilm-stimulatory effect in our CFBE biofilm cell culture
model. Indeed, addition of arginine to the tissue culture medium resulted in the preservation of monolayer integrity after

FIG. 1. Arginine and tobramycin prevent bacterial killing of CFBE
epithelial cells. (A) An uninfected monolayer. (B and C) CFBE cell
monolayers 6 h after inoculation with PA14 in the absence (B) or
presence (C) of 0.4% arginine. (D) Intact CFBE cell monolayer after
8 h of biofilm development with arginine followed by 24 h of incubation with 1,000 g/ml tobramycin. The tobramycin treatment did not
clear the bacteria, which typically persisted at approximately 103 to 104
CFU/well. The images were taken by phase-contrast microscopy and
are representative fields of view from several wells studied. Scale
bars ⫽ 120 m. (E) Treatment of 5-h coculture biofilms with 1 g/ml
tobramycin (Tb) for 2 h resulted in a small but significant reduction in
bacterial virulence toward the CFBE cells compared to untreated
samples. *, P ⬍ 0.05. (F) CFU determination of the biofilm cultures in
panel E revealed equal bacterial titers in tobramycin-treated and untreated biofilms. The difference between the 0-g/ml tobramycin and
1-g/ml tobramycin samples was not statistically significant. The error
bars indicate 1 standard deviation.

incubation with PA14 for up to ⬃9 h (Fig. 1C). Incubation for
longer than 9 h resulted in monolayer destruction, even in the
presence of arginine (data not shown). Enumeration of bacterial CFU bound to the epithelial cells after 1 h of incubation in
the presence or absence of arginine revealed the same number
of P. aeruginosa cells bound under both conditions, suggesting
that arginine might affect downstream events in biofilm formation or might otherwise impact epithelial cell cytotoxicity (data
not shown). We have termed this model of P. aeruginosa
growth on epithelial cells the “static coculture biofilm system.”
We next sought to determine whether the extended CFBE
cell viability afforded by arginine was sufficient to support biofilm formation. We inoculated the static coculture biofilm system with PA14/pSMC21 (plasmid pSMC21 expresses GFP
constitutively) (2). Fluorescence microscopy revealed clusters
of P. aeruginosa cells scattered across the epithelial cell mono-
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FIG. 2. PA14 forms biofilm microcolonies on a CFBE epithelial
cell monolayer. (A and B) Incubation of CFBE cells with PA14/
pSMC21 (GFP) resulted in clusters of GFP-PA14 scattered across the
monolayer (A) that appeared as microcolonies bound to the surfaces
of the cells (B). Panels A and B are phase-contrast images overlaid
with the GFP channel. (C) Staining with calcofluor resulted in blue
fluorescence of the microcolonies, as seen in a phase-contrast image
overlaid with the blue channel. Scale bars ⫽ 120 m (A) or 35 m (B
and C). (D) CFBE cells were inoculated with wild-type PA14 or strains
carrying mutations in the flgK or pilB gene. Bacterial CFU determined
at 7 h postinfection revealed ⬎10-fold reduction in bacterial populations on cells infected with the flgK or pilB mutant. *, P ⬍ 0.05
compared to PA14. The error bars indicate 1 standard deviation.

layer within 6 to 8 h after inoculation (Fig. 2A). These clusters
appeared to be attached to the epithelial cells, and they exhibited a mushroom-like morphology reminiscent of large P.
aeruginosa macrocolonies developed on abiotic surfaces (7,
40). This structured architecture differentiated these macrocolonies from the “flat” biofilm phenotypes that P. aeruginosa
can also form (21). We also observed PA14 as planktonic
bacteria and in a variety of other biofilm stages, including
reversibly and irreversibly bound individual bacteria and microcolonies of various sizes (Fig. 2B and data not shown).
These morphological observations suggested that PA14 forms
biofilms on the CFBE cells. We next conducted additional experiments to determine whether the clusters of P. aeruginosa displayed properties typical of biofilms. One of the key features of
bacterial biofilms is the production and secretion of an exopolysaccharide matrix that surrounds the biofilm bacteria (7). To
demonstrate the presence of a polysaccharide matrix around the
microcolony-like structures attached to the epithelial cells, we
stained the bacteria with calcofluor, a fluorescent dye that binds
to ␤(1-3) and ␤(1-4) polysaccharide linkages found in the biofilm
matrices produced by many microorganisms (52). As expected,
calcofluor stained these microcolonies (Fig. 2C).
To provide additional support for the view that the microcolonies on CFBE cells were biofilms, we inoculated CFBE cell
monolayers with PA14 strains carrying mutations in the flgK or
pilB gene, which encode components of flagella and the type
IV pilus, respectively (34). Mutations that disrupt the biogenesis of these organelles negatively impact biofilm formation on
abiotic surfaces (34). The type IV pilus is also an important
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attachment factor for epithelial cell binding (48). After inoculation in the static CFBE coculture system with the flgK and
pilB mutant strains, we assessed biofilm formation at 7 h by
determination of the numbers of bacterial CFU attached to the
epithelial cells. Similar to abiotic biofilm systems, the flgK and
pilB mutants exhibited a marked decrease in bacterial CFU
bound to the CFBE cells compared to wild-type PA14 (Fig.
2D). These findings underscore the similar requirements for
biofilm formation on biotic and abiotic surfaces.
Bacterial colonies on the CFBE cells were extremely resistant to antibiotic treatment, another hallmark of biofilms. We
treated static CFBE/PA14 biofilms for 24 h with up to 1,000
g/ml tobramycin, a concentration measured in the lungs of
CF patients (13). In this experiment, we measured ⬎103 CFU/
well remaining on the cells after antibiotic treatment (data not
shown), suggesting that the minimum bactericidal concentration was greater than 1,000 g/ml tobramycin. CFU counts
before the antibiotic treatment were comparable to those in
Fig. 2D (approximately 108 CFU/well). The antibiotic concentrations used during this treatment surpassed the minimum
bactericidal concentration of tobramycin for planktonic PA14
and for abiotically grown PA14 biofilms (8 g/ml and 400
g/ml, respectively), as measured in a previous study from our
group (32). We have also tested the antibiotic resistance of
CFBE-grown biofilms by adding tobramycin at early time
points in the presence and absence of arginine with no apparent difference in tobramycin resistance. PA14 grown on CFBE
cells in the presence and absence of arginine displayed similar
high-level tobramycin resistance (data not shown). Visualization of the epithelial monolayer after treatment of static
CFBE/PA14 biofilms for 24 h with up to 1,000 g/ml tobramycin showed that the CFBE cell monolayer was intact, and
the CFBE cells appeared similar to uninoculated epithelial
cells (Fig. 1D). Thus, even though ⬃103 CFU/well of viable
PA14 remained in the biofilm on the CBFE cells after tobramycin treatment, the bacteria did not kill the epithelial cells for
at least 24 h.
The data above suggested that tobramycin treatment of P.
aeruginosa biofilms on CFBE cells results in a decrease in the
virulence of the microorganism toward the epithelial cells.
Alternatively, decreased killing of the epithelial cells might
have resulted from a lower number of bacteria. To distinguish
between these possibilities, we tested a range of tobramycin
concentrations for their effects on CFBE/PA14 biofilm CFU
and cytotoxicity. We found that incubation of CFBE/PA14
biofilms with 1 g/ml tobramycin elicited a small but significant
decrease in bacterial cytotoxicity toward CFBE cells as measured by release of LDH from the epithelial cells (Fig. 1E) but
had no effect on the biofilm CFU (Fig. 1F). Tobramycin concentrations above 1 g/ml resulted in a decrease in both cytotoxicity and biofilm CFU (data not shown). These results suggest that tobramycin may exert two separable effects upon P.
aeruginosa biofilms on CFBE cells: a decrease in viable bacteria and a decrease in bacterial virulence.
Microarray analysis of tobramycin-treated airway cells. The
preceding results suggested that tobramycin might reduce the
virulence of P. aeruginosa biofilms growing on CF-derived airway cells. Accordingly, microarray studies were conducted to
identify genes that regulate virulence in response to tobramycin treatment. To accomplish this goal, we performed a mi-
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croarray analysis of PA14 biofilms grown on CFBE cells
treated with tobramycin. While treatment with 1 g/ml tobramycin resulted in a significant decrease in bacterial cytotoxicity
(Fig. 1E), this change was small, and we suspected that many
transcriptional responses to tobramycin might be obscured by
this low antibiotic dose. We therefore chose to treat CFBE/
PA14 biofilms with 500 g/ml tobramycin, and 30 min was
chosen for the treatment time to be able to capture the early
responses of PA14 biofilms to tobramycin. This concentration
of tobramycin was 50% of the minimum bactericidal concentration for CFBE-grown biofilms (see above). Furthermore,
CFBE/PA14 biofilms displayed antibiotic resistance phenotypes and epithelial cell viabilities when treated with 500 g/ml
tobramycin at 24 h similar to those in the experiments with
1,000 g/ml tobramycin treatment described above (Fig. 1D).
To generate RNA for microarray studies, PA14 biofilms
were grown on CFBE monolayers using the static system for
9 h. At that time, replicate samples were incubated in the
presence or absence of 500 g/ml tobramycin for 30 min,
whereupon bacterial RNA was harvested and prepared for
microarray analysis as described in Materials and Methods.
The microarray study was performed with triplicate samples,
and a Bayesian analysis was used to provide a statistical assessment of significance (19, 24, 28). We chose cutoffs of ⱖ2.0-fold
and an ln P value of ⬍0.05. Overall, we found 338 bacterial
transcripts that were upregulated upon tobramycin treatment
and 500 transcripts that were downregulated (see Tables S3
and S4 in the supplemental material). Because tobramycin
reduced PA14 virulence toward CFBE cells (Fig. 1D), we predicted that virulence-related genes would be downregulated by
tobramycin. Most notably, we found that PQS biosynthesis was
highly downregulated (Table 1). We also observed a decrease
in transcript levels for phenazine synthesis (phnA, ⫺15.3;
phnB, ⫺7.2), hydrogen cyanide synthesis (hcnA, ⫺2.6; hcnB,
⫺3.2; hcnC, ⫺3.9), pyoverdine activity (pvdA, ⫺4.2; pvdD,
⫺3.1; pvdE, ⫺4.8; pvdS, ⫺4.3; fpvA, ⫺26.3), and a probable
phospholipase (PA3487, ⫺3.0) (see Tables S3 and S4 in the
supplemental material). However, there were no changes in
the transcript levels of other known lipases or proteases. Three
transcripts related to type III secretion were downregulated
(pscE, ⫺3.2; pscI, ⫺2.6; and PA1692, ⫺3.0), but no other type
III gene was significantly changed (see Tables S3 and S4 in the
supplemental material).
Intriguingly, we found very little change in known antibiotic
resistance-related genes. Transcript levels for a probable drug
efflux transporter gene (PA1541) were increased 2.9-fold (see
Table S3 in the supplemental material), but the efflux transporter gene mexB was downregulated 2.4-fold and the mexR
repressor was upregulated 2.5-fold. Furthermore, we saw no
change in transcript levels for any other known or probable
antibiotic-related genes, including aph, bacA, cat, str, and other
mex genes (see Tables S3 and S4 in the supplemental material).
These results suggest that the antibiotic resistance of P. aeruginosa biofilms on epithelial cells may involve the expression of
other, unknown factors.
One theory put forth to explain increased antibiotic resistance of biofilms is the presence of specialized “persister” cells
(26, 44). While few genes associated with this persister phenotype have been identified, none of these genes, including glpD,
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TABLE 1. Selected genes stimulated or repressed by tobramycin in
CFBE/PA14 biofilmsa
Gene

Fold
change

PQS
PA0996
PA0997
PA0998
PA0999
PA1000

⫺2.5
⫺19.5
⫺15.0
⫺10.1
⫺13.8

Alginate
PA0762
PA0763
PA5262
PA5255
PA5261
PA5253
PA0764

⫹8.6
⫹6.5
⫹3.6
⫹2.8
⫹2.8
⫹2.1
⫹2.0

Iron
PA3531
PA4764
PA0362
PA4131
PA3491
PA5217

⫹16.5
⫹4.2
⫹2.1
⫺2.0
⫺2.0
⫺2.3

PA5216

⫺2.4

PA3812
PA3813
PA2399
PA3809
PA2386
PA2426
PA4231

⫺2.5
⫺2.8
⫺3.1
⫺3.4
⫺4.2
⫺4.3
⫺4.4

PA2397
PA4225
PA4226
PA4228
PA4221
PA2398
PA4229
PA4230

⫺4.8
⫺6.1
⫺7.7
⫺13.9
⫺25.3
⫺26.3
⫺28.9
⫺29.9

Magnesium
PA4635
PA0913
PA4825

⫹8.2
⫹3.9
⫹2.8

Description

pqsA (biosynthesis of PQS)
pqsB (biosynthesis of PQS)
pqsC (biosynthesis of PQS)
pqsD (biosynthesis of PQS)
pqsE (biosynthesis of PQS)
algU (sigma factor)
mucA (anti-sigma factor)
algZ (alginate biosynthesis protein)
algQ (alginate biosynthesis regulator)
algR (alginate biosynthesis regulator)
algP (alginate biosynthesis regulator)
mucB (alginate biosynthesis negative
regulator)
bfrB (bacterioferritin)
fur (ferric uptake regulation)
fdx1 (ferridoxin)
Probable iron-sulfur protein
Probable ferredoxin
Probable binding protein component
of ABC iron transporter
Probable permease of ABC iron
transporter
iscA (probable iron-binding protein)
iscU (probable iron-binding protein)
pvdD (pyoverdine synthetase)
fdx2 (ferridoxin)
pvdA (pyoverdine synthesis)
pvdS (sigma factor, iron responsive)
pchA (salicylate biosynthesis, pyochelin
biosynthesis)
pvdE (pyoverdine synthesis)
pchF (pyochelin synthetase)
pchE (pyochelin synthesis)
pchD (pyochelin synthesis)
fptA (pyochelin receptor precursor)
fpvA (ferripyoverdine receptor)
pchC (pyochelin synthesis)
pchB (salicylate biosynthesis, pyochelin
synthesis)
hypothetical MgtC protein
mgtE (magnesium transport)
mgtA (magnesium transport)

a
The table shows the overall trends of several metabolic activities. Full microarray data can be found in the supplemental information.

gpsA, and plsB (45), displayed any change in transcript level in
response to tobramycin in our study.
Despite modest changes in antibiotic and virulence gene
expression, several interesting trends arose from our microarray analysis. For instance, several genes in the alginate regulatory cascade were highly upregulated by tobramycin (Table
1), including algU, mucA, and algZ (33, 36). However, there
was no significant change in the expression of the core alg
biosynthetic genes (e.g., algD), indicating that the increased
expression of alginate-regulatory genes we observed in our
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microarray might not result in a corresponding increase in
alginate production.
Finally, numerous genes related to the synthesis and export
of iron chelators were highly downregulated by tobramycin
treatment, including pchB, pchC, pchA, fptA, fpvA, and pvdD
(Table 1). Iron siderophores have been associated with the
virulence of a number of different bacterial species, and thus,
a reduction in the expression of these genes could account, at
least in part, for the observed decrease in virulence (27).
The impacts of tobramycin on gene expression differ in
planktonic cells, biofilms grown on abiotic surfaces, and biofilms grown on airway cells. To determine the impact of tobramycin treatment on planktonic bacteria, we performed further microarray analysis of planktonic P. aeruginosa treated
with a subinhibitory concentration of tobramycin. Exponentialphase bacteria were treated with 5 g/ml tobramycin for 30
min, and RNA was prepared for microarray analysis as
described in Materials and Methods. This tobramycin concentration was chosen because it is approximately 50% of the
planktonic minimum bactericidal concentration for the microorganism (32), analogous to the tobramycin dose used in the
microarray studies of biofilm-grown bacteria described above.
This planktonic subinhibitory concentration did not affect bacterial CFU during the time course of the experiment (data not
shown). RNA from untreated planktonic cultures was used as
a control.
We observed that far fewer genes were regulated under
these conditions, with only 23 transcripts upregulated and 21
transcripts downregulated (see Tables S5 and S6 in the supplemental material). Additionally, the magnitude of these
changes was much lower. The most highly upregulated gene
from the planktonic microarray data set (PA4762) was increased only 3.6-fold, compared to the 37.5-fold increase observed for PA5471 in the CFBE/PA14 biofilm microarray (see
Tables S3 and S5 in the supplemental material). Similarly, the
maximally downregulated gene in the planktonic microarray
(PA0284) was decreased 5.8-fold, compared to the maximum
decrease of 29.9-fold (PA4230) found in the biofilm microarray
(see Tables S4 snd S6 in the supplemental material). The
decreased number of genes regulated and the lower magnitude
of transcriptional changes seen in this planktonic data set may
be due to the relatively low level of antibiotic treatment (5
g/ml tobramycin) compared with treatment of CFBE-grown
biofilms (500 g/ml tobramycin). Many of the genes upregulated in the planktonic microarray encode heat shock-related
proteins, such as grpE, hslU, and dnaK (see Table S5 in the
supplemental material). The downregulated genes included a
locus encoding sulfate binding and transport (PA0280 to
PA0283), as well as a gene cluster encoding a probable ABC
transport system (PA3441 to PA3446) (see Table S6 in the
supplemental material).
When we compared the response of CFBE/PA14 biofilms
treated with tobramycin to that of planktonic bacteria treated
with tobramycin, we found little similarity between the two
groups of data (Table 2; see Fig. S1 in the supplemental material). There were only two genes upregulated and only five
genes downregulated under both conditions. Eight genes
showed opposite effects between planktonic and biofilm cultures (upregulated in planktonic culture but downregulated in
biofilms). These results suggest that the bacteria in biofilms on

TABLE 2. Comparison of biofilm and planktonic microarrays
Overlap

Gene

Description

CFBE up/planktonic
up
PA0320
PA4205

Conserved hypothetical
protein
Hypothetical protein

CFBE down/planktonic
down
PA0283
PA0284
PA2204
PA3330
PA3931

sbp (sulfate-binding protein)
Hypothetical protein
Probable component of ABC
transporter
Probable short-chain
dehydrogenase
Probable protease

CFBE down/planktonic
up
PA0779
PA1596
PA4385
PA4386
PA4761
PA4762
PA5052
PA5054

Probable ATP-dependent
protease
htpG (heat shock protein)
groEL (chaperone-heat shock)
groES (chaperone-heat shock)
dnaK (chaperone-heat shock)
grpE (heat shock protein)
Hypothetical protein
hslU (heat shock protein)

epithelial cells react very differently to tobramycin than their
planktonic P. aeruginosa counterparts.
Several years ago, Whiteley et al. published a microarray
study of P. aeruginosa biofilms on granite surfaces treated with
tobramycin (47). While this study reported transcriptional
changes in only 20 genes, a comparison of their results on an
abiotic surface with our CFBE/P. aeruginosa microarray results
revealed several differences in transcriptional profiles between
tobramycin-treated biofilms grown on abiotic surfaces and
CFBE cells (see Table S7 and Fig. S1 in the supplemental
material). Only four genes were upregulated in both data sets,
and we found no overlap among downregulated genes. On the
other hand, two of the tobramycin-upregulated genes on abiotic surfaces were downregulated in our study (the stress response factor genes groES and dnaK). Similar differences were
seen when we compared the Whiteley et al. data with our
planktonic microarray data (see Table S7 and Fig. S1 in the
supplemental material). When we compared all three microarray studies, we discovered that no genes were upregulated
under all conditions or downregulated under all conditions,
although two genes that were downregulated in CFBE/PA14
biofilms during tobramycin treatment were upregulated in
both abiotic biofilms and planktonic cultures during tobramycin treatment (see Table S7 and Fig. S1 in the supplemental
material).
The differences we observed between our microarray data
set of tobramycin-regulated genes in CFBE/PA14 biofilms and
the microarray data of Whiteley et al. could be due to the very
different experimental conditions in these studies (such as different abiotic surfaces, different media, and different tobramycin concentrations used). To address this issue, we assessed the
expression of a select set of genes from bacteria grown in a
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FIG. 3. Abiotic biofilms respond differently to tobramycin than biofilms on CFBE cells. Quantitative RT-PCR revealed that PA14 biofilms on PVC plastic plates demonstrated an increase in transcriptional
expression of dnaK (A) but no change in pqsA expression (B) in
response to tobramycin (Tb) treatment. On the other hand, tobramycin treatment of CFBE/PA14 biofilms resulted in a decrease in both
dnaK (C) and pqsA (D) expression, as determined by qRT-PCR. *, P ⬍
0.05. The error bars indicate 1 standard deviation.

biofilm on an abiotic surface under conditions very similar to
those used for the CFBE biofilm microarray and planktonic
microarray experiments. PA14 biofilms were grown on a PVC
plastic surface (six-well tissue culture plates without CFBE
cells) for 24 h in MEM tissue culture medium with arginine
supplementation, resulting in a bacterial CFU similar to that of
CFBE/PA14 biofilms and planktonic PA14 populations used in
the microarray experiments described above. The abiotic biofilms were treated for 30 min with 200 g/ml tobramycin. This
concentration of tobramycin was analogous to that used for the
planktonic and CFBE-grown biofilms, that is, 50% of the minimum bactericidal concentration for abiotic PA14 biofilms
(32). Thirty minutes after treatment with the antibiotic, bacterial RNA was harvested as described in Materials and
Methods.
Using qRT-PCR, we showed that PA0913 (mgtE), PA4635
(mgtC), PA4326, and PA5470 were upregulated in abioticgrown biofilms in response to tobramycin treatment (see Fig.
S2 in the supplemental material). We also observed a downregulation in PA3330 and PA4221 (fptA) expression. These
tobramycin-induced changes are similar to those observed in
the microarray analysis of CFBE/PA14 biofilms (see Tables S3
and S4 in the supplemental material).
qRT-PCR analysis of abiotic biofilms also revealed an upregulation of PA4761 (dnaK) and no change in PA0996 (pqsA)
expression in abiotic biofilms in response to tobramycin (Fig.
3A and B), as was observed in the study by Whiteley et al. (47),
in contrast to the downregulation seen in the microarray analysis with both of these genes in CFBE/PA14 biofilms (see
Table S4 in the supplemental material). We confirmed the
downregulation of dnaK and pqsA expression in CFBE/PA14
biofilms by qRT-PCR analysis of tobramycin-treated CFBE/
PA14 biofilms (Fig. 3C and D). Thus, while it is evident that
similarities exist between the responses of biotic and abiotic P.
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aeruginosa biofilms to tobramycin, clearly there are responses
unique to tobramycin-treated CFBE/PA14 biofilms, such as
pqsA transcriptional downregulation.
Mutational analysis. We next created isogenic deletion mutants in a number of genes in PA14 that were upregulated in
the CFBE/PA14 biofilms upon tobramycin treatment. We
tested these mutants for biofilm formation on CFBE cells (by
CFU count), antibiotic sensitivity of the CFBE-grown biofilms,
and virulence toward CFBE cells. While most of these deletion
mutants displayed wild-type phenotypes, we discovered that a
mutant in the gene PA0913 (mgtE) showed increased virulence
on epithelial cells (see Table S8 in the supplemental material).
When inoculated into culture with CFBE cells for 8 h, the
PA0913 mutant damaged the CFBE monolayer, whereas
PA14-infected monolayers remained intact at this time point
(Fig. 4A).
We quantified this virulence effect by measuring the release
of LDH from the epithelial cells to obtain a measure of the
cytotoxicity of the bacteria. Over time, P. aeruginosa elicited a
steady increase in the amount of LDH released from CFBE
cells (see Fig. S3A in the supplemental material), and this
experiment allowed us to choose the optimal time points at
which to assess the cytotoxicity of wild-type and mutant strains
in our system. When we compared LDH release from CFBE
cells incubated with wild-type PA14 or with the PA0913 mutant, we discovered much greater cytotoxicity of the PA0913
mutant compared to wild-type PA14 (Fig. 4B). Complementation with the full-length gene on a multicopy plasmid attenuated the cytotoxicity of this mutant strain to a level indistinguishable from that of the wild type, and these effects were
seen when PA0913 expression was driven from its natural
promoter or a constitutive promoter (Fig. 4B and data not
shown).
As mentioned above, PA0913 is a probable homolog of
mgtE, encoding the magnesium transporter MgtE. Therefore,
we tested isogenic deletion mutants in other predicted magnesium transporters in PA14, but we did not observe any virulence phenotypes, except with double and triple mutants involving mutation of PA0913 in combination with mutation of
other putative magnesium transporter genes (see Table S8 in
the supplemental material).
Varying biofilm biomass on epithelial cells may alter cytotoxicity due to changing numbers of bacteria. For instance, we
noticed that decreased biofilm formation exhibited by flgK and
pilB mutants (Fig. 2D) also resulted in significantly diminished
cytotoxicity as determined by LDH release from CFBE cell
monolayers (see Fig. S3B in the supplemental material). To
investigate biofilm formation by the PA0913 mutant, we measured bacterial CFU of the biofilm 5 h after inoculation, the
same time at which LDH measurements were made. We found
no difference in numbers of bacteria between the wild type and
the PA0913 mutant biofilms (Fig. 4C), indicating that the cytotoxicity of the PA0913 mutant was increased independently
of the bacterial numbers. We also observed little to no difference in the formation of biofilms between the wild type and the
PA0913 mutant over time using a 96-well PVC plastic plate as
an abiotic surface for biofilm formation (Fig. 4D).
The PA0913 (mgtE) mutant requires the T3SS for increased
virulence. As mentioned above, expression of the T3SS of P.
aeruginosa contributes to the cytotoxicity of epithelial cells.
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FIG. 4. The PA0913 (mgtE) gene affects virulence on CFBE epithelial cells. (A) Microscopic analysis revealed that monolayers infected with
an isogenic deletion mutant in the PA0913 gene (right) were destroyed more quickly than monolayers infected with wild-type PA14 (left) at 8 h
postinoculation. Scale bar ⫽ 120 m. (B) The cytotoxicity of the ⌬PA0913 mutant on the CFBE cells was analyzed at 5 h, as described in Materials
and Methods. The ⌬PA0913 mutant was significantly more cytotoxic than PA14 (*, P ⬍ 0.05), and this effect could be rescued by complementation
with the full-length gene in trans (pPA0913). pMQ72 is the empty vector control. The error bars indicate 1 standard deviation. (C) Determination
of the number of CFU in the biofilms on the CFBE cells demonstrated that a PA0913 isogenic deletion mutant developed bacterial CFU at 5 h
postinoculation similar to that for wild-type PA14. (D) Wild-type PA14 and the ⌬PA0913 mutant displayed similar biofilm formation kinetics on
PVC plastic. Black diamonds, PA14; gray triangles, ⌬PA0913.

The T3SS is also an important virulence factor in lung pathogenesis (31, 42), and considering the contact between P. aeruginosa and CFBE cells in our assays, it seemed likely that T3SS
might be involved in biofilm-dependent cytotoxicity. To investigate the possible involvement of the T3SS in cytotoxicity, we
inoculated CFBE cells with a ⌬pscC deletion mutant, which is
defective for the T3SS (17, 47a). As expected, this ⌬pscC strain
exhibited significantly attenuated cytotoxicity compared to the
wild type in terms of LDH released from the CFBE epithelial
cell monolayer (Fig. 5A). Intriguingly, a double deletion mutant in both pscC and PA0913 demonstrated low-level cytotoxicity, similar to the ⌬pscC strain. Furthermore, release of LDH
from cells incubated with either the ⌬pscC strain or the double
mutant was significantly abrogated compared to the single
⌬PA0913 mutant (Fig. 5A), suggesting that the increased virulence phenotype of the PA0913 mutant requires a functional
T3SS. In support of this hypothesis, we measured PA0913 gene
expression in wild-type and ⌬pscC biofilms by qRT-PCR, and
we found a small but significant decrease in PA0913 transcript
levels in the ⌬pscC mutant (the relative expression level for
⌬pscC was 0.104 ⫾ 0.008 compared to 0.126 ⫾ 0.015 for PA14;
P ⬍ 0.05). On the other hand, qRT-PCR analysis of wild-type
and ⌬PA0913 biofilms revealed no difference in transcript levels of pcrV (PA1706, encoding a component of T3SS) or of
exoT (PA0044, encoding a T3SS-secreted effector protein)
(data not shown). However, we did observe a slight but significant increase in the transcript levels of pcrH (PA1707, encoding a component of T3SS; relative expression in ⌬PA0913,
14.7 ⫾ 2.9 compared to 11.8 ⫾ 2.3 for the wild type; P ⬍ 0.05).
As a control experiment, we inoculated wild-type or mutant
bacteria into MEM tissue culture medium in a Transwell cup

FIG. 5. Roles of T3SS and secreted virulence factors in the PA0913
(mgtE) mutant phenotype. (A) Mutation of PA0913 in the type III
secretion-defective ⌬pscC mutant background eliminates the cytotoxicity observed for the single ⌬PA0913 strain. This cytotoxicity of the
⌬PA0913 ⌬pscC double mutant is similar to that of the single ⌬pscC
mutant. *, P ⬍ 0.05 compared to wild-type PA14; #, P ⬍ 0.05 compared to PA14 and to ⌬PA0913. The error bars indicate 1 standard
deviation. (B and C) We measured pyoverdine (B) and pyocyanin
(C) secreted by PA14 and the ⌬PA0913 mutant in overnight cultures
using colorimetric assays, as described in Materials and Methods.
Slight but significant decreases were seen in pyocyanin and pyoverdine
production in the ⌬PA0913 (mgtE) mutant. *, P ⬍ 0.05.

VOL. 76, 2008

BIOFILMS ON CF AIRWAY CELLS

1431

FIG. 6. Tobramycin stimulates expression of the PA0913 (mgtE) gene in biofilms on CFBE cells. (A) Semiquantitative RT-PCR demonstrated
that tobramycin exposure led to an increase in PA0913 transcript levels in CFBE/PA14 biofilms (left) but not in planktonic cultures (right). fbp
is a constitutively expressed control gene. Tb, tobramycin; ⫺ and ⫹ indicate that cDNA was prepared from untreated samples or tobramycintreated samples, respectively. (B) qRT-PCR revealed a 38.3-fold enhancement of PA0913 gene transcription in PA14 biofilms on CFBE cells
treated with 500 g/ml tobramycin (⫹Tb). *, P ⬍ 0.05. The error bars indicate 1 standard deviation.

suspended above the epithelial cells. In this assay, the Transwell membrane prevented direct contact between the bacteria
and the epithelial cells, but the bacterial supernatants (and
hence, any secreted factors) could freely diffuse across the
Transwell membrane and interact with the monolayer. Similarly, low-molecular-weight epithelial cell products could
diffuse across the Transwell and stimulate bacterial gene expression. We measured the LDH released from Transwellinoculated coculture and found essentially no cytotoxicity with
the wild type or the mutants within the time frame of the
experiment (data not shown). Thus, virulence effects observed
with the PA0913 mutant appear to largely require contactdependent mechanisms, such as the T3SS.
Mutating the PA0913 (mgtE) gene alters pyoverdine and
pyocyanin production. As further controls, we also tested the
levels of known secreted factors in wild-type and PA0913 mutant strains. Using spectrophotometric assays (see Materials
and Methods), we measured pyoverdine and pyocyanin levels
secreted in overnight cultures. Mutation of PA0913 resulted in
a slight but significant decrease in the production of pyoverdine (Fig. 5B) and pyocyanin (Fig. 5C). We found no differences in protease and lipase expression between wild-type and
mutant strains (data not shown), indicating that mutation of
PA0913 did not have broad effects on the production of secreted virulence factors.
Regulation of the PA0913 gene by tobramycin. Our microarray analysis of CFBE/PA14 biofilms treated with tobramycin
indicated that the antibiotic stimulates increased expression of
the PA0913 gene (see Table S3 in the supplemental material).
However, measurement of the cytotoxicity of the PA0913 mutant, as discussed above, was carried out in the absence of
tobramycin, suggesting that regulation of the gene is complex.
To begin to investigate the regulation of the PA0913 gene, we
performed semiquantitative RT-PCR on RNA isolated from
CFBE/PA14 biofilms treated with tobramycin for 30 min. We
found that tobramycin treatment led to a dramatic increase in
the levels of the PA0913 transcript compared to untreated
biofilms (Fig. 6A, left), increasing transcript levels to approximately those observed in planktonic-culture-grown cells (see
below). This result was confirmed by qRT-PCR analysis, revealing a 38-fold (⫾4.0 standard deviation) increase in the
transcriptional levels of PA0913 in CFBE/PA14 biofilm treated
with tobramycin (Fig. 6B). Importantly, low-level expression of

the PA0913 gene was observed in the absence of antibiotic
treatment. This basal expression of PA0913 is likely to account,
at least in part, for the virulence effects seen with biofilms of
wild-type P. aeruginosa versus the PA0913 mutant in coculture
biofilms (Fig. 4).
We next tested whether a similar tobramycin effect on
PA0913 gene expression could be produced in planktonic cultures of PA14. Exponential-phase cultures were treated with a
subinhibitory tobramycin concentration for 30 min, and we
measured RNA levels of the PA0913 transcript by RT-PCR, as
described above. Contrary to the biofilm phenotype observed
above, high-level expression of the gene was observed in untreated planktonic cultures (Fig. 6A, right), and tobramycin
had minimal effects upon the transcript levels of the gene. The
fbp gene was used as a constitutive control in these reactions,
and its transcript level remained unchanged regardless of experimental conditions.
DISCUSSION
We developed a static coculture tissue culture system in
which P. aeruginosa biofilms form directly on human CF-derived airway cells in vitro. Some studies have suggested that P.
aeruginosa initiates biofilm formation within the thick mucus
layer of the CF airways (14). While P. aeruginosa biofilm formation may indeed occur in this mucus layer, it is also known
that P. aeruginosa can interact with and bind to the epithelial
cell surface of the lung, especially in the early stages of lung
colonization (15, 31). Our study demonstrates that bacterial
binding to the epithelial surface can lead to growth of biofilm
microcolonies on the epithelial cells in culture (Fig. 2). The
biofilms that formed on CFBE cells appeared similar to structured, mushroom-like biofilms formed under certain conditions on abiotic surfaces, including glass and mucin (21). The
bacteria were bound to a surface (CFBE cells), were encased in
a polysaccharide matrix (Fig. 2C), required factors necessary
for abiotic-grown biofilms (Fig. 2D), and were extremely resistant to the antibiotic tobramycin. Our coculture biofilm model,
therefore, may be useful for dissecting the early stages of the
intricate relationship between P. aeruginosa and the CF airway
epithelium.
Using our coculture biofilm model, we have discovered two
conditions that influence bacterial virulence: arginine supple-
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mentation and tobramycin treatment (Fig. 1). In regard to
arginine, it is presently unclear why this amino acid inhibits
bacterial virulence (Fig. 1) and promotes biofilm formation on
both biotic and abiotic surfaces. Also unknown is whether
arginine reduces virulence gene expression or upregulates biofilm formation pathways, although several recent studies suggest that these events may be linked (11). It is known that P.
aeruginosa can metabolize arginine via several different pathways (29). Downstream signaling through these metabolic networks might influence the expression of virulence factors. On
the other hand, arginine may act independently of known
mechanisms. Furthermore, it is possible that arginine might
affect the ability of the host cells to resist bacterial toxins and
virulence factors. In any case, it is clear that arginine inhibits
epithelial cell death sufficiently to allow biofilms to form, at
least in the short term (Fig. 2). The role of arginine in biofilm
formation and virulence is the subject of ongoing studies.
Our data indicate that tobramycin treatment of the biofilms
likely impacts virulence in two ways: (i) by decreasing bacterial
viability and (ii) by decreasing virulence. Although this decrease in virulence might be a result of a decreased number of
bacteria after tobramycin treatment, we identified a tobramycin concentration (1 g/ml) that inhibits virulence without
affecting the number of biofilm CFU (Fig. 1E and F). Thus, we
were able to separate these two phenotypes to demonstrate
that tobramycin can specifically inhibit the virulence of P.
aeruginosa biofilms on CF-derived airway cells in culture.
To identify tobramycin-regulated virulence factors, we exposed biofilms grown on airway cells to the antibiotic and
monitored the response via microarray. To our knowledge, this
is the first example of examining the gene expression of P.
aeruginosa grown in biofilms on airway cells. In the wild-type
strain, treatment of biofilms grown on CFBE epithelial cells
with tobramycin induced the expression of a number of genes,
including those that code for the AlgU/MucA/AlgZ regulators
and PA0913, a predicted homolog of the magnesium transporter encoded by mgtE (Fig. 6). While there was no evidence
that tobramycin positively regulated the genes required for
alginate biosynthesis, it is intriguing to speculate that tobramycin treatment of P. aeruginosa infections in the CF lung might
increase production of non-alginate-related genes regulated by
the AlgU/MucA/AlgZ regulatory system.
In regard to the predicted mgtE homolog PA0913, because
mutating the PA0913 gene results in increased virulence but
does not impact the biofilms formed on airway cells (Fig. 4), we
infer that the role of this gene and its product might be the
down-modulation of virulence when bacteria are growing on
airway cells in a biofilm. Consistent with this idea, treatment of
the biofilm with tobramycin both increased PA0913 expression
and decreased virulence. Given that the PA0913 gene codes
for a putative magnesium transporter, we postulate that magnesium homeostasis might be important in the interaction between P. aeruginosa and the host. MEM contains 0.812 mM
Mg2⫹, and it would be interesting to investigate the effects of
altering the magnesium concentration on biofilm formation
and virulence. Interestingly, our genetic studies indicate that
increased virulence of PA0913 requires the T3SS, although the
relationship between PA0913 and the secretion system is unclear. It is important to note that we performed functional
studies on just a small number of the genes that were differ-
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entially expressed upon tobramycin treatment of the biofilms.
Therefore, other genes besides PA0913 may participate in virulence, biofilm formation, or antibiotic resistance in the context of biofilms on airway cells.
Tissue culture systems are often used to investigate host/
pathogen interactions in place of suitable animal models. Intriguingly, there have been a few studies demonstrating bacterial biofilm formation on cultured epithelial cells, including
studies of Haemophilus influenzae and Mycobacterium avium
biofilm formation on cultured human airway cells and Salmonella enterica biofilm formation on HEp-2 liver cells (3, 46, 50).
While many researchers have looked at acute interactions of
planktonic P. aeruginosa with cultured cells in vitro, to our
knowledge, P. aeruginosa biofilm formation on epithelial cells
has not been demonstrated in in vitro systems. Frisk et al. have
reported interactions between P. aeruginosa and primary normal human airway epithelial cells grown as polarized monolayers on transwell inserts in vitro, and they observed these
interactions up to 16 h after inoculation (10). However, no
mention was made of biofilm formation, and the images presented depict individually binding bacteria. Considering our
results, it is unclear why microcolony structures were not observed in the Frisk et al. study, although they used a different
bacterial strain and grew epithelial cells on Transwell supports
instead of on the well bottom, as in our study. Intriguingly,
these researchers used normal airway cells as opposed to the
⌬F508 homozygous cell line that we used here, pointing to a
possible difference in the ability of P. aeruginosa to form biofilms on airway cells depending upon CFTR status. Current
studies in our laboratories are investigating the formation of P.
aeruginosa biofilms on other epithelial cell lines.
The different responses we observed between planktonic
bacteria, CFBE/PA14 biofilms, and abiotic biofilms suggest
physiological differences in P. aeruginosa depending upon environmental conditions (Tables 1 and 2; see Table S3 to S7 in
the supplemental material). Similar to previous findings (1, 7,
47, 50), our results indicate that planktonic P. aeruginosa and
biofilm P. aeruginosa populations are quite distinct from each
other. Most intriguingly, the surface upon which a biofilm
forms appears to influence responses to antibiotics. Taken
together, our analysis of these three microarray experiments
suggests that biofilm-grown P. aeruginosa reacts very differently
to tobramycin than planktonic P. aeruginosa. While there are
several experimental differences between our CFBE biofilm
microarray study and the abiotic biofilm microarray analysis
published by Whiteley et al., our analysis also indicates that P.
aeruginosa biofilms behave differently when formed on CFBE
epithelial cells versus an abiotic surface (see Table S7 in the
supplemental material). Furthermore, our results suggest that
the use of our coculture biofilm system can reveal novel virulence factors that studies of abiotic biofilms may have missed.
ACKNOWLEDGMENTS
We thank J. Bomberger for assistance with tissue culture and D.
Hogan for donation of primers pqsAF1 and pqsAR1. We also thank S.
Kuchma and K. Brothers for helpful support with qRT-PCR and
microarray experiments.
This work was supported by Postdoctoral Research Fellowship
ANDERS06F0 (G.G.A.) and the CF-Research Development Program
(B.A.S.) (STANTO07R0) from the Cystic Fibrosis Foundation and by
funds from the NIH to G.A.O. (AI51630) and B.A.S. (HL074175).

VOL. 76, 2008

BIOFILMS ON CF AIRWAY CELLS
REFERENCES

1. Anderl, J. N., J. Zahller, F. Roe, and P. S. Stewart. 2003. Role of nutrient
limitation and stationary-phase existence in Klebsiella pneumoniae biofilm
resistance to ampicillin and ciprofloxacin. Antimicrob. Agents Chemother.
47:1251–1256.
2. Bloemberg, G. V., G. A. O’Toole, B. J. Lugtenberg, and R. Kolter. 1997.
Green fluorescent protein as a marker for Pseudomonas spp. Appl. Environ.
Microbiol. 63:4543–4551.
3. Boddicker, J. D., N. A. Ledeboer, J. Jagnow, B. D. Jones, and S. Clegg. 2002.
Differential binding to and biofilm formation on, HEp-2 cells by Salmonella
enterica serovar Typhimurium is dependent upon allelic variation in the fimH
gene of the fim gene cluster. Mol. Microbiol. 45:1255–1265.
4. Boucher, R. C. 2004. New concepts of the pathogenesis of cystic fibrosis lung
disease. Eur. Respir. J. 23:146–158.
5. Bruscia, E., F. Sangiuolo, P. Sinibaldi, K. K. Goncz, G. Novelli, and D. C.
Gruenert. 2002. Isolation of CF cell lines corrected at DeltaF508-CFTR
locus by SFHR-mediated targeting. Gene Ther. 9:683–685.
6. Caiazza, N. C., and G. A. O’Toole. 2004. SadB is required for the transition
from reversible to irreversible attachment during biofilm formation by
Pseudomonas aeruginosa PA14. J. Bacteriol. 186:4476–4485.
7. Costerton, J. W., Z. Lewandowski, D. E. Caldwell, D. R. Korber, and H. M.
Lappin-Scott. 1995. Microbial biofilms. Annu. Rev. Microbiol. 49:711–745.
8. Cozens, A. L., M. J. Yezzi, K. Kunzelmann, T. Ohrui, L. Chin, K. Eng, W. E.
Finkbeiner, J. H. Widdicombe, and D. C. Gruenert. 1994. CFTR expression
and chloride secretion in polarized immortal human bronchial epithelial
cells. Am. J. Respir. Cell Mol. Biol. 10:38–47.
9. Essar, D. W., L. Eberly, A. Hadero, and I. P. Crawford. 1990. Identification
and characterization of genes for a second anthranilate synthase in Pseudomonas aeruginosa: interchangeability of the two anthranilate synthases and
evolutionary implications. J. Bacteriol. 172:884–900.
10. Frisk, A., J. R. Schurr, G. Wang, D. C. Bertucci, L. Marrero, S. H. Hwang,
D. J. Hassett, and M. J. Schurr. 2004. Transcriptome analysis of Pseudomonas aeruginosa after interaction with human airway epithelial cells. Infect.
Immun. 72:5433–5438.
11. Furukawa, S., S. L. Kuchma, and G. A. O’Toole. 2006. Keeping their options
open: acute versus persistent infections. J. Bacteriol. 188:1211–1217.
12. Gallagher, L. A., and C. Manoil. 2001. Pseudomonas aeruginosa PAO1 kills
Caenorhabditis elegans by cyanide poisoning. J. Bacteriol. 183:6207–6214.
13. Geller, D. E., W. H. Pitlick, P. A. Nardella, W. G. Tracewell, and B. W.
Ramsey. 2002. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122:219–226.
14. Gibson, R. L., J. L. Burns, and B. W. Ramsey. 2003. Pathophysiology and
management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit.
Care Med. 168:918–951.
15. Gomez, M. I., and A. Prince. 2007. Opportunistic infections in lung disease:
Pseudomonas infections in cystic fibrosis. Curr. Opin. Pharmacol. 7:244–251.
16. Govan, J. R., and V. Deretic. 1996. Microbial pathogenesis in cystic fibrosis:
mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev.
60:539–574.
17. Hogan, D. A., A. Vik, and R. Kolter. 2004. A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol. Microbiol. 54:1212–1223.
18. Hoiby, N., B. Frederiksen, and T. Pressler. 2005. Eradication of early
Pseudomonas aeruginosa infection. J. Cyst. Fibros. 4(Suppl. 2):49–54.
19. Irizarry, R. A., B. Hobbs, F. Collin, Y. D. Beazer-Barclay, K. J. Antonellis, U.
Scherf, and T. P. Speed. 2003. Exploration, normalization, and summaries of
high density oligonucleotide array probe level data. Biostatistics 4:249–264.
20. Kim, E. K., W. H. Jang, J. H. Ko, J. S. Kang, M. J. Noh, and O. J. Yoo. 2001.
Lipase and its modulator from Pseudomonas sp. strain KFCC 10818: prolineto-glutamine substitution at position 112 induces formation of enzymatically
active lipase in the absence of the modulator. J. Bacteriol. 183:5937–5941.
21. Kirisits, M. J., and M. R. Parsek. 2006. Does Pseudomonas aeruginosa use
intercellular signalling to build biofilm communities? Cell. Microbiol. 8:1841–
1849.
22. Kjelleberg, S., and S. Molin. 2002. Is there a role for quorum sensing signals
in bacterial biofilms? Curr. Opin. Microbiol. 5:254–258.
23. Ko, Y. H., and P. L. Pedersen. 2001. Cystic fibrosis: a brief look at some
highlights of a decade of research focused on elucidating and correcting the
molecular basis of the disease. J. Bioenerg. Biomembr. 33:513–521.
24. Kuchma, S. L., J. P. Connolly, and G. A. O’Toole. 2005. A three-component
regulatory system regulates biofilm maturation and type III secretion in
Pseudomonas aeruginosa. J. Bacteriol. 187:1441–1454.
25. Lam, J., R. Chan, K. Lam, and J. W. Costerton. 1980. Production of mucoid
microcolonies by Pseudomonas aeruginosa within infected lungs in cystic
fibrosis. Infect. Immun. 28:546–556.
26. Lewis, K. 2005. Persister cells and the riddle of biofilm survival. Biochemistry
70:267–274.

Editor: A. Camilli

1433

27. Litwin, C. M., and S. B. Calderwood. 1993. Role of iron in regulation of
virulence genes. Clin. Microbiol. Rev. 6:137–149.
28. Long, A. D., H. J. Mangalam, B. Y. Chan, L. Tolleri, G. W. Hatfield, and P.
Baldi. 2001. Improved statistical inference from DNA microarray data using
analysis of variance and a Bayesian statistical framework. Analysis of global
gene expression in Escherichia coli K12. J. Biol. Chem. 276:19937–19944.
29. Lu, C. D., Z. Yang, and W. Li. 2004. Transcriptome analysis of the ArgR
regulon in Pseudomonas aeruginosa. J. Bacteriol. 186:3855–3861.
30. Lyczak, J. B., C. L. Cannon, and G. B. Pier. 2000. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes
Infect. 2:1051–1060.
31. Lyczak, J. B., C. L. Cannon, and G. B. Pier. 2002. Lung infections associated
with cystic fibrosis. Clin. Microbiol. Rev. 15:194–222.
32. Mah, T. F., B. Pitts, B. Pellock, G. C. Walker, P. S. Stewart, and G. A.
O’Toole. 2003. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic
resistance. Nature 426:306–310.
33. Nichols, W. W., S. M. Dorrington, M. P. Slack, and H. L. Walmsley. 1988.
Inhibition of tobramycin diffusion by binding to alginate. Antimicrob. Agents
Chemother. 32:518–523.
34. O’Toole, G. A., and R. Kolter. 1998. Flagellar and twitching motility are
necessary for Pseudomonas aeruginosa biofilm development. Mol. Microbiol.
30:295–304.
35. O’Toole, G. A., L. A. Pratt, P. I. Watnick, D. K. Newman, V. B. Weaver, and
R. Kolter. 1999. Genetic approaches to study of biofilms. Methods Enzymol.
310:91–109.
36. Patel, R. 2005. Biofilms and antimicrobial resistance. Clin. Orthop. Relat.
Res. 437:41–47.
37. Sadikot, R. T., T. S. Blackwell, J. W. Christman, and A. S. Prince. 2005.
Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am. J.
Respir. Crit. Care Med. 171:1209–1223.
38. Saiman, L., and J. Siegel. 2004. Infection control in cystic fibrosis. Clin.
Microbiol. Rev. 17:57–71.
39. Sato, H., and D. W. Frank. 2004. ExoU is a potent intracellular phospholipase. Mol. Microbiol. 53:1279–1290.
40. Sauer, K., A. K. Camper, G. D. Ehrlich, J. W. Costerton, and D. G. Davies.
2002. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J. Bacteriol. 184:1140–1154.
41. Shanks, R. M., N. C. Caiazza, S. M. Hinsa, C. M. Toutain, and G. A.
O’Toole. 2006. Saccharomyces cerevisiae-based molecular tool kit for manipulation of genes from gram-negative bacteria. Appl. Environ. Microbiol.
72:5027–5036.
42. Shaver, C. M., and A. R. Hauser. 2004. Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect.
Immun. 72:6969–6977.
43. Singh, P. K., A. L. Schaefer, M. R. Parsek, T. O. Moninger, M. J. Welsh, and
E. P. Greenberg. 2000. Quorum-sensing signals indicate that cystic fibrosis
lungs are infected with bacterial biofilms. Nature 407:762–764.
44. Spoering, A. L., and K. Lewis. 2001. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J.
Bacteriol. 183:6746–6751.
45. Spoering, A. L., M. Vulic, and K. Lewis. 2006. GlpD and PlsB participate in
persister cell formation in Escherichia coli. J. Bacteriol. 188:5136–5144.
46. Starner, T. D., N. Zhang, G. Kim, M. A. Apicella, and P. B. McCray, Jr. 2006.
Haemophilus influenzae forms biofilms on airway epithelia: implications in
cystic fibrosis. Am. J. Respir. Crit. Care Med. 174:213–220.
47. Whiteley, M., M. G. Bangera, R. E. Bumgarner, M. R. Parsek, G. M. Teitzel,
S. Lory, and E. P. Greenberg. 2001. Gene expression in Pseudomonas aeruginosa biofilms. Nature 413:860–864.
47a.Wolfgang, M. C., V. T. Lee, M. E. Gilmore, and S. Lory. 2003. Coordinate
regulation of bacterial virulence genes by a novel adenylate cyclase-dependent signaling pathway. Dev. Cell 4:253–263.
48. Woods, D. E., D. C. Straus, W. G. Johanson, Jr., V. K. Berry, and J. A. Bass.
1980. Role of pili in adherence of Pseudomonas aeruginosa to mammalian
buccal epithelial cells. Infect. Immun. 29:1146–1151.
49. Yahr, T. L., and M. C. Wolfgang. 2006. Transcriptional regulation of the
Pseudomonas aeruginosa type III secretion system. Mol. Microbiol. 62:631–
640.
50. Yamazaki, Y., L. Danelishvili, M. Wu, E. Hidaka, T. Katsuyama, B. Stang,
M. Petrofsky, R. Bildfell, and L. E. Bermudez. 2006. The ability to form
biofilm influences Mycobacterium avium invasion and translocation of bronchial epithelial cells. Cell. Microbiol. 8:806–814.
51. Yoon, S. S., and D. J. Hassett. 2004. Chronic Pseudomonas aeruginosa infection in cystic fibrosis airway disease: metabolic changes that unravel novel
drug targets. Expert Rev. Anti. Infect. Ther. 2:611–623.
52. Zogaj, X., M. Nimtz, M. Rohde, W. Bokranz, and U. Romling. 2001. The
multicellular morphotypes of Salmonella typhimurium and Escherichia coli
produce cellulose as the second component of the extracellular matrix. Mol.
Microbiol. 39:1452–1463.

